BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, announces the development of a sublingual thin-film oral dissolvable film (ODF) for Semaglutide, internally identified as BNT24005. This innovative product is intended to address limitations of existing administration methods for a therapeutic developed by Novo Nordisk, with the aim of improving patient accessibility and convenience. This product is currently under development and remains subject to regulatory review and approval.
Semaglutide: A Proven Therapeutic Leader
Semaglutide, developed by Novo Nordisk and marketed under brand names such as Ozempic® and Wegovy®, has revolutionized treatment for Type 2 diabetes and obesity. By mimicking glucagon-like peptide-1 (GLP-1), it enhances insulin secretion, reduces appetite, and slows gastric emptying, offering powerful tools for glycemic control and weight management.
In 2023, Semaglutide generated over $14 billion in revenue globally, reflecting surging demand for effective diabetes and obesity treatments (The Washington Post).
The BioNxt Advantage
Despite Semaglutide's success, its injectable format presents barriers, including needle anxiety and challenges with long-term adherence. BioNxt's sublingual thin-film technology, BNT24005, offers a novel delivery system that aims to reduce these hurdles, improving the overall patient experience.
Key benefits of the sublingual thin-film include:
Needle-Free Convenience: A painless and discreet alternative to injections.
Rapid Absorption: Direct sublingual delivery for faster therapeutic action.
Enhanced Bioavailability: Reduced enzymatic degradation compared to traditional oral routes.
Improved Patient Compliance: A portable, user-friendly format designed to encourage long-term adherence.
This next-generation delivery method has the potential to address unmet needs in diabetes and obesity care, aligning with global trends favoring patient-centric solutions.
Significant Market Opportunity
The global burden of diabetes and obesity underscores the growing need for innovative treatments. According to the International Diabetes Federation, over 537 million adults worldwide are living with diabetes, and the prevalence of obesity continues to rise.
Semaglutide's existing market success highlights the potential for innovative delivery systems. BioNxt aims to address patient challenges while adhering to stringent regulatory and intellectual property standards.
Strategic Development and Patent Positioning
BioNxt's thin-film innovation focuses on enhancing drug delivery methods without infringing on existing molecule patents. The product leverages a strategy centered on patentable administration improvements, respecting the intellectual property of Novo Nordisk.
BioNxt's Broader Pipeline of Innovations
The Semaglutide thin-film, BNT24005, is part of BioNxt's broader portfolio of advanced drug delivery technologies, targeting therapeutic areas such as neurodegenerative diseases, metabolic disorders, and other high-need markets. BioNxt's platforms include sublingual thin-films, transdermal patches, and enteric-coated oral tablets, all designed to enhance patient outcomes and healthcare accessibility.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements regarding the development, potential benefits, and commercialization of BioNxt's sublingual thin-film product for Semaglutide. These statements are based on current expectations and projections about future events but involve risks and uncertainties outside of the Company's control. Risks include challenges in obtaining regulatory approvals, potential intellectual property disputes or claims from third parties, and uncertainties associated with product development, manufacturing, and clinical validation. Additional risks include the potential for limited market acceptance of the sublingual thin-film technology and competitive pressures within the diabetes and obesity therapeutic sectors. Readers are cautioned that actual results may differ materially from those expressed in these forward-looking statements due to these and other factors. BioNxt Solutions Inc. undertakes no obligation to update forward-looking statements, except as required by applicable laws.
Trademarks: Trademarks Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S and are referenced in this document solely for informational and comparative purposes to contextualize the market landscape. BioNxt Solutions Inc. is neither affiliated with nor endorsed by Novo Nordisk A/S.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Masar Destination Achieves LEED for Communities Gold Certification23.1.2026 21:35:00 CET | Press release
Affirming its Commitment to Sustainability MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar's adoption of an integrated approach that places people and the environment at the heart of its design and planning processes. This accomplishment reflects the company's commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future. Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construc
Sir Ivan Releases "Love Is The Piece"23.1.2026 20:45:00 CET | Press release
The Peace Anthem of the 21st Century MIAMI, FLORIDA / ACCESS Newswire / January 23, 2026 / Electronic Dance Music (EDM) recording artist, Sir Ivan, has co-written and recorded a peace song that will stand the test of time. Inspired by 20th-century anti-war rock legends such as John Lennon and Bob Dylan, Sir Ivan's new single, "Love Is The Piece," is a bold reminder to all generations that love remains the only path to peace and is found only in our hearts. Stream/Download On All Platforms "As the son of an Auschwitz survivor (see UnstoppableSiggi.com), my life has been deeply affected by the tragedy of having over 50 family members murdered during the Holocaust, simply because they were Jewish. My father's miraculous survival and my subsequent birth had a purpose. And that purpose was for me to one day write and sing a peace song that would help stop violence, bloodshed, and war between people. That song is ‘Love Is The Piece,'" declared Sir Ivan. While global conflicts and civil unres
From NASA to Your Boardroom: Freelancer Opens 85-Million-Mind Innovation Engine to All Enterprises23.1.2026 14:00:00 CET | Press release
The platform that slashed NASA's R&D costs and compressed three-day computations into one hour is now available to any organisation Previous challenge winner's spacecraft solution is bound for space What do you do when your toughest technical problem stumps every expert in your building? If you're NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same. SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide. The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can't crack. The results speak louder than any pit
Datavault AI Inc. Completes Acquisition of API Media23.1.2026 12:00:00 CET | Press release
Technology Provider API Media extends Datavault AI and the patented ADIO Technology to the Live Outdoor Event Market PHILADELPHIA, PA / ACCESS Newswire / January 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset tokenization technologies, today announced that it has closed its previously announced acquisition of API Media Innovation Inc ("API"), a provider of media infrastructure and event technology solutions. API, headquartered in New Jersey, has a decades-long tradition of providing innovative audio and visual technologies to the world of media, sports, and entertainment. API's clients include some of the most prestigious and sought-after sports venues and events, made possible through a dedicated and customer-first culture cultivated over decades. "We are pleased to complete this acquisition, which marks a decisive next step in our strategy to scale Datavault AI's propr
Aviwell Closes €11 Million Series A Investment Round to Scale AI‑Driven Microbiota Platform for Sustainable Animal Nutrition23.1.2026 06:01:00 CET | Press release
TOULOUSE, FRANCE AND BOSTON, MA / ACCESS Newswire / January 23, 2026 / Aviwell SAS, a deep‑tech animal nutrition company headquartered in Toulouse, today announced the successful completion of a €11 million Series A investment round, welcoming three new investors: Blue Revolution Fund (BRF), Blast.Club, and SWEN Capital Partners. The financing will support Aviwell's next phase of growth as the company scales its AI‑driven microbiome discovery and development platform and advances native, nature‑based biological solutions for global agri‑food markets, initially focused on poultry and aquaculture. Built on decades of research pioneered by Aviwell's co‑Founder, Prof. Remy BURCELIN, into how naturally occurring bacterial ecologies administered early in life can have a durable impact on animal growth, health, and resilience, Aviwell has developed Aneto™, an AI‑powered microbiome discovery platform. Aneto™ identifies specific molecular mechanisms - modes of action - that enable the selection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom